Immune checkpoint blockade (ICB) therapy, such as anti-programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) antibodies, has revolutionized the management of virus-associated HCC.2 This evidence concerns the gene PDCD1 and hepatocellular carcinoma.